Alife Health , a health tech company advancing the future of fertility care with artificial intelligence, today announced that Embryo Predict, its AI-powered embryo selection tool, has received CE Mark certification under the European Medical Device Regulation MDR. This approval marks a new era for Alifes expansion into international markets and brings its cutting-edge technology to healthcare providers throughout Europe.
Embryo Predict is a deep learning-based software platform designed to support embryologists in selecting the best embryo for transfer. By integrating directly with existing lab infrastructure, the system captures embryo images, automatically generates an AI score, and ranks embryos according to their likelihood of resulting in a clinical pregnancy. This provides embryologists with consistent, data-driven insights to support embryo selection and brings a new level of standardization to the lab.
Embryo Predict was developed to address one of the most important, yet highly subjective, aspects of IVF: embryo grading. Traditional embryo assessment relies on manual observation of morphology, which can vary significantly between embryologists. Embryo Predict digitizes and standardizes this process, adding an additional layer of quality control and harnessing the power of AI to detect patterns of success from a vast dataset, providing data-driven insights that go beyond the limits of the human eye or the judgment of any single individual.